The Effect of Berberine on Polycystic Ovary Syndrome Patients with Insulin Resistance (PCOS-IR): A Meta-Analysis and Systematic Review

Table 5

The result of meta-analysis regarding the effectiveness of CPA+BBR versus CPA.

Indices	SMD	95CI	P	Trials involved
BMI^◆6♣6◆7♣7	-0.235^◥☆	-0.681~0.211	0.302^◎	No. 6, No. 7, No. 8
WHR^◆6♣6◆7♣7	-0.942^◥☆	-1.755~-0.129	0.023	No. 6, No. 7, No. 8
FSH	2.807^◥	-2.688~8.301	0.317^◎	No. 6, No. 8
LH^◆6	-0.723^◤☆	-1.111~-0.335	0.001	No. 6, No. 8
T^◆6♣6	-0.484^◥☆	-1.062~0.093	0.100^◎	No. 6, No. 8
FPG^◆6◆7	-0.688^◤☆	-0.936~-0.441	0.001	No. 6, No. 7, No. 8, No. 9
FIN^◆6◆7♣7	-0.620^◤☆	-0.893~-0.348	0.001	No. 6, No. 7, No. 9
HOMA-IR^◆6◆7♣7	-0.713^◤☆	-1.026~-0.400	0.001	No. 6, No. 7, No. 8
TC^◆6◆7♣7	-3.816^◥☆	-6.188~-1.444	0.002	No. 6, No. 7, No. 8, No. 9
TG^◆6◆7♣7	-1.516^◥☆	-2.112~-0.920	0.001	No. 6, No. 7, No. 8, No. 9
LDL-C^◆6◆7	-1.173^◥☆	-1.661~-0.685	0.001	No. 6, No. 7, No. 9
HDL-C^◆6◆7	1.452^◤	1.152~1.752	0.001	No. 6, No. 7, No. 9

Notes:
significant statistical difference (P<0.05) between final value and baseline in CPA+BBR group was reported by trial No. x.
significant statistical difference (P<0.05) between final value and baseline in CPA group was reported by trial No. x.
Statistical difference between final value and baseline in each group was not reported in trial No. 8 and 9.
^◤:fixed effect model;^◥:random effect model.
^◎: P>0.05; : P<0.05; : P<0.01; : P<0.001.
^☆: CPA+BBR group showed a greater change than CPA before and after treatment.